Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis

J. M. Mondesir, J. M. Bidart, A. Goodman, G. F. Alberici, P. Caille, F. Troalen, J. Rouesse, C. Bohuon, R. J. Gralla, A. I. Einzig

Research output: Contribution to journalArticle

15 Scopus citations


Drug-dependent antibodies were investigated in patients treated with elleptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers ≥ 32 were at risk for hemolysis. The possible mechanisms are discussed.

Original languageEnglish (US)
Pages (from-to)735-740
Number of pages6
JournalJournal of Clinical Oncology
Issue number5
Publication statusPublished - Jan 1 1985


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this